RedHill Biopharma (RDHL) H1 2024 earnings summary

Executive summary

• Achieved significant operational transformation, focusing on value-driven strategy, cost efficiency, and financial streamlining, with a strengthened cash position after the Movantik Termination Agreement.

• Pipeline de-risked through U.S. government collaborations, targeting oncology, pandemic preparedness, radioprotection, and metabolic diseases.

• Maintained U.S. market leadership for Talicia with a streamlined commercial team and expanded international presence.

Financial highlights

• Net revenues for H1 2024 were $2.6M, down from $5.4M in H1 2023, mainly due to lower Talicia sales and negative Movantik revenues from product returns.

• Gross profit was $1.2M, down from $3M year-over-year, reflecting reduced Talicia prescriptions and cost-cutting.

• Operating loss was $8.4M, compared to operating income of $24.7M in H1 2023; excluding 2023's Movantik one-time gains, operating loss improved by $9.9M.

• Net loss was $3.1M, compared to net income of $51M in H1 2023; adjusted net loss improved by $9.5M year-over-year.

• Cash balance as of June 30, 2024, was $8.2M; net cash used in operations was $6.2M, a significant reduction from $17.8M in H1 2023.

Outlook and guidance

• Multiple late-stage and government-funded clinical programs ongoing, with catalysts expected from new studies, regulatory milestones, and potential new market entries.

• Enrollment in the RHB-107 COVID-19 Phase 2 trial expected to complete in H1 2025.

• New H. pylori treatment guidelines and manufacturing developments may enhance Talicia's market position.